Firefly Neuroscience financials
$1.62−4.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $514.0K | $485.0K | $412.0K | $388.0K | $299.0K | $43.0K | $53.0K | $33.0K |
| Gross profit | $253.0K | $221.0K | $182.0K | $146.0K | $274.0K | $43.0K | $53.0K | $33.0K |
| Gross margin | 49.2% | 45.6% | 44.2% | 37.6% | 91.6% | 100.0% | 100.0% | 100.0% |
| Operating income | -$2.0M | -$2.0M | -$2.5M | -$2.7M | -$1.6M | -$2.1M | -$3.4M | -$4.3M |
| Net income | -$2.0M | -$2.1M | -$2.7M | -$2.6M | -$1.8M | -$17.3M | -$3.8M | -$4.3M |
| Net margin | −386.0% | −431.8% | −660.0% | −680.2% | −613.0% | −40325.6% | −7141.5% | −12997.0% |
| Diluted EPS | $-0.10 | $-0.13 | $-0.20 | $-0.20 | $-0.14 | $-1.74 | $-0.43 | $-0.61 |
| EBITDA | -$1.9M | -$2.0M | -$2.4M | -$2.4M | -$1.6M | -$2.0M | -$2.5M | -$4.3M |
| Operating cash flow | -$1.8M | -$1.9M | -$1.8M | -$1.5M | -$2.4M | -$2.5M | -$1.2M | -$2.5M |
| Free cash flow | -$1.8M | -$2.0M | -$1.8M | -$1.6M | -$2.4M | -$2.5M | -$1.3M | -$2.5M |
| Diluted shares | 20.6M | 16.2M | 13.7M | 13.5M | 12.7M | 10.0M | 8.7M | 7.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.2M | $3.1M | $2.7M | $4.3M | $5.9M | $9.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $16.8M | $10.9M | $10.5M | $12.4M | $14.9M | $12.4M |
| Total liabilities | $2.1M | $2.5M | $2.8M | $2.8M | $2.8M | $7.2M |
| Shareholders' equity | $14.7M | $8.4M | $7.6M | $9.7M | $12.1M | $5.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology